Posted by Defense World Staff on Jun 16th, 2024
Nexalin Technology (NASDAQ:NXL – Get Free Report) is one of 76 public companies in the “Electromedical equipment” industry, but how does it weigh in compared to its rivals? We will compare Nexalin Technology to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations.
This table compares Nexalin Technology and its rivals revenue, earnings per share (EPS) and valuation.
Nexalin Technology’s rivals have higher revenue and earnings than Nexalin Technology. Nexalin Technology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 45.1% of shares of all “Electromedical equipment” companies are owned by institutional investors. 27.7% of Nexalin Technology shares are owned by insiders. Comparatively, 14.9% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Nexalin Technology and its rivals’ net margins, return on equity and return on assets.
This is a breakdown of current ratings and target prices for Nexalin Technology and its rivals, as reported by MarketBeat.com.
As a group, “Electromedical equipment” companies have a potential upside of 24.54%. Given Nexalin Technology’s rivals higher probable upside, analysts clearly believe Nexalin Technology has less favorable growth aspects than its rivals.
Nexalin Technology has a beta of 5.13, indicating that its share price is 413% more volatile than the S&P 500. Comparatively, Nexalin Technology’s rivals have a beta of 12.49, indicating that their average share price is 1,149% more volatile than the S&P 500.
Nexalin Technology rivals beat Nexalin Technology on 8 of the 10 factors compared.
(Get Free Report)
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Receive News & Ratings for Nexalin Technology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Nexalin Technology and related companies with MarketBeat.com’s FREE daily email newsletter.
Head-To-Head Review: Sound Group (NASDAQ:SOGP) & Eventbrite (NYSE:EB)
Cim LLC Purchases Shares of 31,804 ProShares UltraPro Short 20+ Year Treasury (NYSEARCA:TTT)
